Infectious and malignant complications of tnf inhibitor therapy in ibd

American Journal of Gastroenterology

Volumn 108, Issue 12, 2013, Pages 1835-1842

  Targownik, Laura E ^a   Bernstein, Charles N ^a  

^a UNIVERSITY OF MANITOBA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; CERTOLIZUMAB PEGOL; CORTICOSTEROID; ETANERCEPT; IMMUNOMODULATING AGENT; INFLIXIMAB; ISONIAZID; LAMIVUDINE; MERCAPTOPURINE; METHOTREXATE; PLACEBO; PREDNISONE; TUMOR NECROSIS FACTOR INHIBITOR;

CANCER INCIDENCE; CANCER REGRESSION; CANCER RISK; CROHN DISEASE; DISEASE ACTIVITY; DISEASE SEVERITY; DRUG EXPOSURE; DRUG SURVEILLANCE PROGRAM; DRUG UTILIZATION; ENTERITIS; FULMINANT HEPATIC FAILURE; HEPATITIS B; HEPATITIS C; HEPATOSPLENIC T CELL LYMPHOMA; HERPES ZOSTER; HISTOPLASMOSIS; HUMAN; INFECTION; INFECTION RISK; LATENT TUBERCULOSIS; MALIGNANT NEOPLASTIC DISEASE; MELANOMA SKIN CANCER; MILIARY TUBERCULOSIS; NON MELANOMA SKIN CANCER; NONHODGKIN LYMPHOMA; OPPORTUNISTIC INFECTION; PRIORITY JOURNAL; PSORIASIS; REVIEW; RHEUMATOID ARTHRITIS; SINGLE DRUG DOSE; SYSTEMIC MYCOSIS; T CELL LYMPHOMA; TUBERCULOSIS; ULCERATIVE COLITIS; VIRUS REPLICATION;

HUMANS; INFLAMMATORY BOWEL DISEASES; NEOPLASMS; OPPORTUNISTIC INFECTIONS; RISK FACTORS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84889673425     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1038/ajg.2013.294     Document Type: Review

References (87)

1. Colombel JF, Sandborn WJ, Rutgeerts P et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: The CHARM trial. Gastroenterology 2007; 132 : 52-65.
2. Hanauer SB, Feagan BG, Lichtenstein GR et al. Maintenance infliximab for Crohn's disease: The ACCENT I randomised trial. Lancet 2002; 359 : 1541-9.
3. Reinisch W, Sandborn WJ, Rutgeerts P et al. Long-term infliximab maintenance therapy for ulcerative colitis: The ACT-1 and -2 extension studies. Inflamm Bowel Dis 2012; 18 : 201-11.
4. Rutgeerts P, Sandborn WJ, Feagan BG et al. infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005; 353 : 2462-76.
5. Bernstein CN, Fried M, Krabshuis JH et al. World Gastroenterology Organization Practice Guidelines for the diagnosis and management of IBD in 2010. Inflamm Bowel Dis 2010; 16 : 112-24.
6. Mowat C, Cole A, Windsor A et al. Guidelines for the management of inflammatory bowel disease in adults. Gut 2011; 60 : 571-607.
7. Kornbluth A, Sachar DB. Ulcerative colitis practice guidelines in adults: American College Of Gastroenterology, practice parameters committee. Am J Gastroenterol 2010; 105 : 501-23; quiz 24.
8. Chaparro M, Panes J, Garcia V et al. Long-term durability of infliximab treatment in Crohn's disease and effi cacy of dose " escalation " in patients losing response. J Clin Gastroenterol 2011; 45 : 113-8.
9. DHaens G, Baert F, van Assche G et al. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: An open randomised trial. Lancet 2008; 371 : 660-7.
10. Nugent Z, Blanchard JF, Bernstein CN. A population-based study of health-care resource use among infliximab users. Am J Gastroenterol 2010; 105 : 2009-16.
11. Kindler V, Sappino AP, Grau GE et al. The inducing role of tumor necrosis factor in the development of bactericidal granulomas during BCG infection . Cell 1989; 56 : 731-40.
12. Mercer LK, Green AC, Galloway JB et al. The infl uence of anti-TNF therapy upon incidence of keratinocyte skin cancer in patients with rheumatoid arthritis: Longitudinal results from the British Society for Rheumatology Biologics Register. Ann Rheum Dis 2012; 71 : 869-74.
13. Algood HM, Lin PL, Flynn JL. Tumor necrosis factor and chemokine interactions in the formation and maintenance of granulomas in tuberculosis. Clin Infect Dis 2005; 41 (Suppl 3) : S189-93.
14. Targan SR, Hanauer SB, van Deventer SJ et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med 1997; 337 : 1029-35.
15. Kaneko H, Yamada H, Mizuno S et al. Role of tumor necrosis factor-alpha in Mycobacterium-induced granuloma formation in tumor necrosis factor-alpha-defi cient mice. Lab Invest 1999; 79 : 379-86.
16. Toruner M, Loftus EV Jr, Harmsen WS et al. Risk factors for opportunistic infections in patients with inflammatory bowel disease. Gastroenterology 2008; 134 : 929-36.
17. Singh JA, Wells GA, Christensen R et al. Adverse effects of biologics: A network meta-analysis and Cochrane overview. Cochrane Database Syst Rev 2011 : 2 : CD008794.
18. Elting LS, Cooksley C, Bekele BN et al. Generalizability of cancer clinical trial results: Prognostic diff erences between participants and nonparticipants . Cancer 2006; 106 : 2452-8.
19. Grijalva CG, Chen L, Delzell E et al. Initiation of tumor necrosis factoralpha antagonists and the risk of hospitalization for infection in patients with autoimmune diseases. JAMA 2011; 306 : 2331-9.
20. Lichtenstein GR, Feagan BG, Cohen RD et al. Serious infection and mortality in patients with Crohn's disease: More than 5 years of follow-up in the TREAT registry. Am J Gastroenterol 2012; 107 : 1409-22.
21. Keane J, Gershon S, Wise RP et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 2001; 345 : 1098-104.
22. Salmon-Ceron D, Tubach F, Lortholary O et al. Drug-specifi c risk of non-tuberculosis opportunistic infections in patients receiving anti-TNF therapy reported to the 3-year prospective French RATIO registry. Ann Rheum Dis 2011; 70 : 616-23.
23. Wallis RS, Broder MS, Wong JY et al. Granulomatous infectious diseases associated with tumor necrosis factor antagonists. Clin Infect Dis 2004; 38 : 1261-5.
24. Van Assche G, Lewis JD, Lichtenstein GR et al. The London position statement of the World Congress of Gastroenterology on Biological therapy for IBD with the European Crohn's and Colitis Organisation: Safety. Am J Gastroenterol 2011; 106 : 1594-602; quiz 3, 603.
25. Clark M, Colombel JF, Feagan BC et al. American gastroenterological association consensus development conference on the use of biologics in the treatment of inflammatory bowel disease, June 21-23, 2006. Gastroenterology 2007; 133 : 312-39.
26. Carmona L, Gomez-Reino JJ, Rodriguez-Valverde V et al. effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists. Arthritis Rheum 2005; 52 : 1766-72.
27. Mow WS, Abreu-Martin MT, Papadakis KA et al. High incidence of anergy in inflammatory bowel disease patients limits the usefulness of PPD screening before infliximab therapy. Clin Gastroenterol Hepatol 2004; 2 : 309-13.
28. Schoepfer AM, Flogerzi B, Fallegger S et al.comparison of interferongamma release assay versus tuberculin skin test for tuberculosis screening in inflammatory bowel disease. Am J Gastroenterol 2008; 103 : 2799-806.
29. Qumseya BJ, Ananthakrishnan AN, Skaros S et al. QuantiFERON TB gold testing for tuberculosis screening in an inflammatory bowel disease cohort in the United States. Inflamm Bowel Dis 2011; 17 : 77-83.
30. Jauregui-Amezaga A, Turon F, Ordas I et al. Risk of developing tuberculosis under anti-TNF treatment despite latent infection screening. J Crohns Colitis 2013; 7 : 208-12.
31. Lee JH, Slifman NR, Gershon SK et al. Life-threatening histoplasmosis complicating immunotherapy with tumor necrosis factor alpha antagonists infliximab and etanercept. Arthritis Rheum 2002; 46 : 2565-70.
32. Smith JA, Kauff man CA. Endemic fungal infections in patients receiving tumour necrosis factor-alpha inhibitor therapy. Drugs 2009; 69 : 1403-15.
33. Hage CA, Wood KL, Winer-Muram HT et al. Pulmonary cryptococcosis after initiation of anti-tumor necrosis factor-alpha therapy. Chest 2003; 124 : 2395-7.
34. Lee EJ, Song R, Park JN et al. Chronic necrotizing pulmonary aspergillosis in a patient treated with a tumor necrosis factor-alpha inhibitor. Int J Rheum Dis 2010; 13 : E16-9.
35. Wendling D, Murad M, Mathieu S et al. Systemic nocardiosis in a case of rheumatoid arthritis treated with tumor necrosis factor blockers. J Rheumatol 2008; 35 : 539-42.
36. Carroll MB, Forgione MA. Use of tumor necrosis factor alpha inhibitors in hepatitis B surface antigen-positive patients: A literature review and potential mechanisms of action. Clin Rheumatol 2010; 29 : 1021-9.
37. Lee YH, Bae SC, Song GG. Hepatitis B virus (HBV) reactivation in rheumatic patients with hepatitis core antigen (HBV occult carriers) undergoing anti-tumor necrosis factor therapy. Clin Exp Rheumatol 2013; 31 : 118-21.
38. Yeo W, Chan PK, Ho WM et al. Lamivudine for the prevention of hepatitis B virus reactivation in hepatitis B s-antigen seropositive cancer patients undergoing cytotoxic chemotherapy. J Clin Oncol 2004; 22 : 927-34.
39. Yeo W, Johnson PJ. Diagnosis, prevention and management of hepatitis B virus reactivation during anticancer therapy. Hepatology 2006; 43 : 209-20.
40. Lok AS, McMahon BJ. Chronic hepatitis B: Update 2009. Hepatology 2009; 50 : 661-2.
41. Lin MV, Blonski W, Buchner AM et al. The infl uence of anti-TNF therapy on the course of chronic hepatitis C virus infection in patients with inflammatory bowel disease. Dig Dis Sci 2013; 58 : 1149-56.
42. Ferri C, Ferraccioli G, Ferrari D et al. Safety of anti-tumor necrosis factor-alpha therapy in patients with rheumatoid arthritis and chronic hepatitis C virus infection. J Rheumatol 2008; 35 : 1944-9.
43. Brunasso AM, Puntoni M, Gulia A et al. Safety of anti-tumour necrosis factor agents in patients with chronic hepatitis C infection: A systematic review. Rheumatology (Oxford) 2011; 50 : 1700-11.
44. Lavagna A, Bergallo M, Daperno M et al. infliximab and the risk of latent viruses reactivation in active Crohn's disease. Inflamm Bowel Dis 2007; 13 : 896-902.
45. Marehbian J, Arrighi HM, Hass S et al. Adverse events associated with common therapy regimens for moderate-to-severe Crohn's disease. Am J Gastroenterol 2009; 104 : 2524-33.
46. Strangfeld A, Listing J, Herzer P et al. Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-alpha agents. JAMA 2009; 301 : 737-44.
47. Winthrop KL, Baddley JW, Chen L et al. Association between the initiation of anti-tumor necrosis factor therapy and the risk of herpes zoster. JAMA 2013; 309 : 887-95.
48. Zhang J, Xie F, Delzell E et al. Association between vaccination for herpes zoster and risk of herpes zoster infection among older patients with selected immune-mediated diseases. JAMA 2012; 308 : 43-9.
49. Helbling D, Breitbach TH, Krause M. Disseminated cytomegalovirus infection in Crohn's disease following anti-tumour necrosis factor therapy. Eur J Gastroenterol Hepatol 2002; 14 : 1393-5.
50. Greenstein AJ, Sachar DB, Smith H et al. Cancer in universal and left -sided ulcerative colitis: Factors determining risk. Gastroenterology 1979; 77 : 290-4.
51. Ekbom A, Helmick C, Zack M et al. Ulcerative colitis and colorectal cancer. A population-based study. N Engl J Med 1990; 323 : 1228-33.
52. Rutter M, Saunders B, Wilkinson K et al. Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis. Gastroenterology 2004; 126 : 451-9.
53. Bernstein CN, Blanchard JF, Kliewer E et al. Cancer risk in patients with inflammatory bowel disease: A population-based study. Cancer 2001; 91 : 854-62.
54. Loftus EV Jr, Tremaine WJ, Habermann TM et al. Risk of lymphoma in inflammatory bowel disease. Am J Gastroenterol 2000 ; 95 : 2308-12.
55. Lewis JD, Bilker WB, Brensinger C et al. Inflammatory bowel disease is not associated with an increased risk of lymphoma. Gastroenterology 2001; 121 : 1080-7.
56. Kandiel A, Fraser AG, Korelitz BI et al. Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine. Gut 2005; 54 : 1121-5.
57. Beaugerie L, Brousse N, Bouvier AM et al. Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: A prospective observational cohort study. Lancet 2009; 374 : 1617-25.
58. Bongartz T, Sutton AJ, Sweeting MJ et al. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: Systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 2006; 295 : 2275-85.
59. Askling J, Fahrbach K, Nordstrom B et al. Cancer risk with tumor necrosis factor alpha (TNF) inhibitors: Meta-analysis of randomized controlled trials of adalimumab, etanercept, and infliximab using patient level data. Pharmacoepidemiol Drug Saf 2011; 20 : 119-30.
60. Moulis G, Sommet A, Bene J et al. Cancer risk of anti-TNF-alpha at recommended doses in adult rheumatoid arthritis: A meta-analysis with intention to treat and per protocol analyses. PLoS One 2012; 7 : E48991.
61. Peyrin-Biroulet L, Deltenre P, de Suray N et al. Effi cacy and safety of tumor necrosis factor antagonists in Crohn's disease: Meta-analysis of placebo-controlled trials. Clin Gastroenterol Hepatol 2008; 6 : 644-53.
62. Mariette X, Matucci-Cerinic M, Pavelka K et al. Malignancies associated with tumour necrosis factor inhibitors in registries and prospective observational studies: A systematic review and meta-analysis. Ann Rheum Dis 2011; 70 : 1895-904.
63. Lopez-Olivo MA, Tayar JH, Martinez-Lopez JA et al. Risk of malignancies in patients with rheumatoid arthritis treated with biologic therapy: A meta-analysis. JAMA 2012; 308 : 898-908.
64. Haynes K, Beukelman T, Curtis JR et al. Tumor necrosis factor alpha inhibitor therapy and cancer risk in chronic immune-mediated diseases. Arthritis Rheum 2013; 65 : 48-58.
65. http://www.fda.gov/ohrms/dockets/ac/03/transcripts/3930T1.htm; accessed 8 May 2013.
66. Geborek P, Bladstrom A, Turesson C et al. Tumour necrosis factor blockers do not increase overall tumour risk in patients with rheumatoid arthritis, but may be associated with an increased risk of lymphomas. Ann Rheum Dis 2005; 64 : 699-703.
67. Herrinton LJ, Liu L, Weng X et al. Role of thiopurine and anti-TNF therapy in lymphoma in inflammatory bowel disease. Am J Gastroenterol 2011; 106 : 2146-53.
68. Siegel CA, Marden SM, Persing SM et al. Risk of lymphoma associated with combination anti-tumor necrosis factor and immunomodulator therapy for the treatment of Crohn's disease: A meta-analysis. Clin Gastroenterol Hepatol 2009; 7 : 874-81.
69. Vos AC, Bakkal N, Minnee RC et al. Risk of malignant lymphoma in patients with inflammatory bowel diseases: A Dutch nationwide study. Inflamm Bowel Dis 2011; 17 : 1837-45.
70. Ferreri AJ, Govi S, Pileri SA. Hepatosplenic gamma-delta T-cell lymphoma. Crit Rev Oncol Hematol 2012; 83 : 283-92.
71. Kotlyar DS, Osterman MT, Diamond RH et al. A systematic review of factors that contribute to hepatosplenic T-cell lymphoma in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol 2011 ; 9 : 36-41 e1.
72. Deepak P, Sifuentes H, Sherid M et al. T-cell non-Hodgkin's lymphomas reported to the FDA AERS with tumor necrosis factor-alpha (TNF-alpha) inhibitors: Results of the REFURBISH study. Am J Gastroenterol 2013; 108 : 99-105.
73. Wolfe F, Michaud K. Biologic treatment of rheumatoid arthritis and the risk of malignancy: Analyses from a largeus observational study. Arthritis Rheum 2007; 56 : 2886-95.
74. Amari W, Zeringue AL, McDonald JR et al. Risk of non-melanoma skin cancer in a national cohort of veterans with rheumatoid arthritis. Rheumatology (Oxford) 2011; 50 : 1431-9.
75. Long MD, Herfarth HH, Pipkin CA et al. Increased risk for nonmelanoma skin cancer in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol 2010; 8 : 268-74.
76. Singh H, Nugent Z, Demers AA et al. Increased risk of nonmelanoma skin cancers among individuals with inflammatory bowel disease. Gastroenterology 2011; 141 : 1612-20.
77. Peyrin-Biroulet L, Khosrotehrani K, Carrat F et al. Increased risk for nonmelanoma skin cancers in patients who receive thiopurines for inflammatory bowel disease. Gastroenterology 2011 ; 141 : 1621-8 e1-5.
78. Sands BE, Tremaine WJ, Sandborn WJ et al. infliximab in the treatment of severe, steroid-refractory ulcerative colitis: A pilot study. Inflamm Bowel Dis 2001; 7 : 83-8.
79. Hanauer SB, Sandborn WJ, Rutgeerts P et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: The CLASSIC-I trial. Gastroenterology 2006; 130 : 323-33; quiz 591.
80. Present DH, Rutgeerts P, Targan S et al. infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med 1999; 340 : 1398-405.
81. Rutgeerts P, DHaens G, Targan S et al. Effi cacy and safety of retreatment with anti-tumor necrosis factor antibody (infl iximab) to maintain remission in Crohn's disease. Gastroenterology 1999; 117 : 761-9.
82. Sandborn WJ, Hanauer SB, Katz S et al. Etanercept for active Crohn's disease: A randomized, double-blind, placebo-controlled trial. Gastroenterology 2001; 121 : 1088-94.
83. Sandborn WJ, Feagan BG, Stoinov S et al. Certolizumab pegol for the treatment of Crohn's disease. N Engl J Med 2007; 357 : 228-38.
84. Sandborn WJ, Hanauer SB, Rutgeerts P et al. Adalimumab for maintenance treatment of Crohn's disease: Results of the CLASSIC II trial. Gut 2007; 56 : 1232-9.
85. Schreiber S, Rutgeerts P, Fedorak RN et al. A randomized, placebocontrolled trial of certolizumab pegol (CDP870) for treatment of Crohn's disease. Gastroenterology 2005; 129 : 807-18.
86. Schreiber S, Khaliq-Kareemi M, Lawrance IC et al. Maintenance therapy with certolizumab pegol for Crohn's disease. N Engl J Med 2007; 357 : 239-50.
87. Sandborn WJ, Rutgeerts P, Feagan BG et al. Colectomy rate comparison after treatment of ulcerative colitis with placebo or infliximab. Gastroenterology 2009; 137 : 1250-60; quiz 520.